Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Lemmens

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Acta Clinica Belgica|September 24, 2021
Cobalamin and folic acid deficiencies presenting with features of a thrombotic microangiopathy: a case seriesBritt Ceuleers, Sofie Stappers, Jan Lemmens, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 21, 2007
Paraplegia after 30 Gy involved field irradiation (IFRT) on the mediastinum for Hodgkin's diseaseCaroline Sweldens, Reinhilde Weytjens, José Thomas, et al.
Annals of Hematology|February 9, 2011
CML with e6a2 BCR-ABL1 transcript: an aggressive entity?Karolien Anne Beel, Jan Lemmens, Hilde Vranckx, et al.
British Journal of Haematology|February 13, 2010
The t(14;20)(q32;q12): a rare cytogenetic change in multiple myeloma associated with poor outcomeMarie-Christiane Vekemans, Heidi Lemmens, Michel Delforge, et al.
Cancers|July 14, 2023
Disease Perception Is Correlated with Health-Related Quality of Life in Patients Suffering from Myelodysplastic Syndromes: Results of the Belgian Be-QUALMS StudyBert Heyrman, Stef Meers, Ann De Becker, et al.
Ejhaem|October 17, 2024
Real-life data of luspatercept in lower-risk myelodysplastic syndromes advocate new research objectivesBert Heyrman, Stef Meers, Sélim Sid, et al.
Acta Clinica Belgica|February 23, 2017
Results from the Belgian mantle cell lymphoma registryVibeke Vergote, Ann Janssens, Marc André, et al.
Leukemia Research|March 26, 2014
Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromesMichel Delforge, Dominik Selleslag, Yves Beguin, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Acta Clinica Belgica|September 24, 2021
Cobalamin and folic acid deficiencies presenting with features of a thrombotic microangiopathy: a case seriesBritt Ceuleers, Sofie Stappers, Jan Lemmens, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 21, 2007
Paraplegia after 30 Gy involved field irradiation (IFRT) on the mediastinum for Hodgkin's diseaseCaroline Sweldens, Reinhilde Weytjens, José Thomas, et al.
Annals of Hematology|February 9, 2011
CML with e6a2 BCR-ABL1 transcript: an aggressive entity?Karolien Anne Beel, Jan Lemmens, Hilde Vranckx, et al.
British Journal of Haematology|February 13, 2010
The t(14;20)(q32;q12): a rare cytogenetic change in multiple myeloma associated with poor outcomeMarie-Christiane Vekemans, Heidi Lemmens, Michel Delforge, et al.
Cancers|July 14, 2023
Disease Perception Is Correlated with Health-Related Quality of Life in Patients Suffering from Myelodysplastic Syndromes: Results of the Belgian Be-QUALMS StudyBert Heyrman, Stef Meers, Ann De Becker, et al.
Ejhaem|October 17, 2024
Real-life data of luspatercept in lower-risk myelodysplastic syndromes advocate new research objectivesBert Heyrman, Stef Meers, Sélim Sid, et al.
Acta Clinica Belgica|February 23, 2017
Results from the Belgian mantle cell lymphoma registryVibeke Vergote, Ann Janssens, Marc André, et al.
Leukemia Research|March 26, 2014
Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromesMichel Delforge, Dominik Selleslag, Yves Beguin, et al.
Pageof 1